New cancer drug combo tested for safety in advanced tumors
NCT ID NCT05661578
Summary
This study tested the safety and how the body processes a new two-drug immunotherapy combination for people with advanced solid cancers that had spread or returned. The trial involved 64 participants with specific tumor characteristics who had not received similar immune-based treatments before. Researchers primarily monitored for side effects while also checking drug levels in the blood and immune responses.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PD-L1-SELECTED SOLID TUMORS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Asan Medical Center - PPDS
Seoul, 05505, South Korea
-
C.H. Regional Reina Sofia - PPDS
Córdoba, 14004, Spain
-
China Medical University Hospital
Taichung, 40447, Taiwan
-
Chongqing Sanxia Central Hospital
Chongqing, 404000, China
-
Gazi University Medical Faculty
Ankara, 06500, Turkey (Türkiye)
-
General Hospital Pula
Pula, 52000, Croatia
-
Hacettepe Universitesi Tip Fakultesi Hastanesi
Ankara, 06100, Turkey (Türkiye)
-
Hospital Clinico Universitario de Valencia
Valencia, 46010, Spain
-
Hospital Regional Universitario de Malaga ? Hospital General
Málaga, 29010, Spain
-
Hospital Universitario Virgen del Rocio
Seville, 41013, Spain
-
Hospital del Mar
Barcelona, 08003, Spain
-
IASO Obstetrics Gynecology Clinic
Marousi, 151 23, Greece
-
ICO l?Hospitalet ? Hospital Duran i Reynals
L'Hospitalet de Llobregat, Barcelona, 08908, Spain
-
Inonu University Faculty of Medicine Turgut Ozal Medical Center
Malatya, 44280, Turkey (Türkiye)
-
Instituto de Investigacion Oncologica Vall dHebron (VHIO) - EPON
Barcelona, 8035, Spain
-
Klinicki bolnicki centar Zagreb
Zagreb, 10000, Croatia
-
Medical Oncology Associates
Spokane, Washington, 99208, United States
-
Medical Park Seyhan Hospital
Seyhan, 01060, Turkey (Türkiye)
-
Memorial Ankara Hastanesi
Ankara, 06520, Turkey (Türkiye)
-
Memorial Sisli Private Hospital
Istanbul, 34385, Turkey (Türkiye)
-
Namik Kemal University
Alt?nova, 59100, Turkey (Türkiye)
-
National Cancer Center
Goyang-si, 10408, South Korea
-
National Cheng Kung University Hospital
Tainan, 70457, Taiwan
-
National Taiwan University Hospital
Taipei, 10002, Taiwan
-
Oncology Institute of Vojvodina
Kamenitz, 21204, Serbia
-
Oncomed-System
Belgrade, 11000, Serbia
-
START MADRID_Hospital Universiario Fundacion Jimenez Diaz
Madrid, 28040, Spain
-
START Madrid_Hospital Universitario HM Sanchinarro_CIOCC
Madrid, 28050, Spain
-
Seoul National University Bundang Hospital
Seongnam-si, 13605, South Korea
-
Seoul National University Hospital
Seoul, 03080, South Korea
-
St. Luke's Hospital
Thessaloniki, 552 36, Greece
-
TAIPEI VETERANS GENERAL HOSPITAL, Urology
Taipei, 11217, Taiwan
-
University General Hospital of Patras
Pátrai, 265 00, Greece
-
University Hospital Medical Center Bezanijska kosa
Belgrade, 11080, Serbia
Conditions
Explore the condition pages connected to this study.